Metagenomi, Inc. Common Stock (MGX) Total Return Calculator with Dividends Reinvested

Metagenomi, Inc. Common Stock

Popular:

The total return for Metagenomi, Inc. Common Stock (MGX) stock is -18.92% over the past 12 months. So far it's down 28.14% this year. The 5-year total return is -88.36%, meaning $10,000 invested in MGX stock 5 years ago would be worth $1,164 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in MGX 1 year ago, it would be worth $8,451 today — you'd have lost $1,549.

With Dividends Reinvested$8,451-15.49%

Price Only (No DRIP)$8,451-15.49%

Period2025-06-23 → 2026-06-18

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in MGX

1Y$8,108-$1,892 (-18.9%)-18.9% CAGR

3Y$1,164-$8,836 (-88.4%)-51.2% CAGR

5Y$1,164-$8,836 (-88.4%)-35.0% CAGR

10Y$1,164-$8,836 (-88.4%)-19.4% CAGR

15Y$1,164-$8,836 (-88.4%)-13.4% CAGR

20Y$1,164-$8,836 (-88.4%)-10.2% CAGR

30Y$1,164-$8,836 (-88.4%)-6.9% CAGR

Metagenomi, Inc. Common Stock did not pay dividends during this period. Total return = price return.

Loading MGX total return...

As of 2026-06-22

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-28.14%	—	-28.14%	—	$7,186
1Y	-18.92%	-18.92%	-18.92%	—	$8,108
3Y	-88.36%	-51.18%	-88.36%	—	$1,164
5Y	-88.36%	-34.96%	-88.36%	—	$1,164
10Y	-88.36%	-19.35%	-88.36%	—	$1,164
15Y	-88.36%	-13.36%	-88.36%	—	$1,164
20Y	-88.36%	-10.20%	-88.36%	—	$1,164
30Y	-88.36%	-6.92%	-88.36%	—	$1,164

Risk & Highlights

Best Year-57.26%2025

Worst Year-64.99%2024

Max Drawdown-65.97%2025-10-20 → 2026-06-16

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-8.98%	-8.98%	—	+0.41%	-9.4pp
2025	-57.26%	-57.26%	—	+16.64%	-73.9pp
2024	-64.99%	-64.99%	—	+24.00%	-89.0pp

MGX underperformed the S&P 500 by 43.91pp over the past year (-18.92% vs +24.99%).

Loading summary...

MGX Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
MGXMetagenomi, Inc. Common Stock	$45M	-5.5%	-28.1%	-18.9%	—	-88.4%	-88.4%	-88.4%
BEAMBeam Therapeutics Inc.	$3.5B	+27.3%	+25.8%	+100.9%	—	+2.4%	-59.8%	+82.1%
CRSPCRISPR Therapeutics AG	$5.2B	+11.4%	+0.6%	+21.7%	—	-4.9%	-57.7%	+283.9%
EDITEditas Medicine, Inc.	$263M	+6.3%	+31.2%	+14.5%	—	-67.8%	-92.5%	-90.9%
NTLAIntellia Therapeutics, Inc.	$1.8B	+23.5%	+70.1%	+63.2%	—	-64.1%	-79.4%	-43.2%
PRMEPrime Medicine, Inc.	$583M	+14.9%	-8.5%	+79.4%	—	-78.8%	-79.0%	-54.8%
RCKTRocket Pharmaceuticals, Inc.	$366M	+9.1%	-3.2%	+18.4%	—	-85.2%	-92.2%	-89.0%
SGMOSangamo Therapeutics, Inc.	$75M	+41.1%	-59.1%	-63.3%	—	-84.9%	-98.4%	-96.9%
ILMNIllumina, Inc.	$24.6B	+14.4%	+20.5%	+79.4%	—	-17.6%	-63.5%	+18.9%
TMOThermo Fisher Scientific Inc.	$172.7B	+5.1%	-21.4%	+18.8%	+0.5pp	-11.0%	-2.2%	+220.6%
PACBPacific Biosciences of California, Inc.	$435M	+21.7%	-23.9%	+6.9%	—	-89.3%	-95.2%	-84.3%

Compare:MGX vs BEAM MGX vs CRSP MGX vs EDIT MGX vs BEAM vs CRSP

About MGX Dividend Returns

Metagenomi, Inc. Common Stock (MGX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of MGX over the past year?

Metagenomi, Inc. Common Stock (MGX) delivered a return of -18.92% over the past year. Since MGX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in MGX be worth today?

A $10,000 investment in Metagenomi, Inc. Common Stock one year ago would be worth $8,108 today, representing a loss of $1,892.

Q3Does MGX pay dividends?

Metagenomi, Inc. Common Stock (MGX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For MGX, the total return equals the price-only return.

Q4Did MGX beat the S&P 500?

No, Metagenomi, Inc. Common Stock (MGX) underperformed the S&P 500 by 43.91 percentage points over the past year. MGX delivered a total return of -18.92%, compared to the S&P 500's 24.99%. This means a passive S&P 500 index fund outperformed MGX by 43.91pp during this period.

Q5What is MGX's worst drawdown?

Metagenomi, Inc. Common Stock (MGX) experienced a maximum drawdown of -65.97% over the past year, declining from its peak on 2025-10-20 to its trough on 2026-06-16. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is MGX's long-term total return over 10, 20, or 30 years?

Here are Metagenomi, Inc. Common Stock (MGX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -88.4% (-19.4% CAGR) — $10,000 would have grown to $1,164. Over 20 years: -88.4% total return (-10.2% CAGR) — $10,000 → $1,164. Over 30 years: -88.4% total return (-6.9% CAGR) — $10,000 → $1,164. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was MGX's best and worst year?

Metagenomi, Inc. Common Stock's best calendar year was 2025 with a total return of -57.3%. Its worst year was 2024 with a total return of -65.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 7.7 percentage points.

How much would $100/month in MGX be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →